Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval In Mainland China For NERLYNX For Extended Adjuvant Treatment Of Early Stage HER2-Positive Breast Cancer
Benzinga Newsdesk